Aligos Therapeutics, Inc.
ALGS
$5.95
-$0.53-8.18%
| Weiss Ratings | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.75 | |||
| Price History | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -38.41% | |||
| 30-Day Total Return | -66.61% | |||
| 60-Day Total Return | -84.50% | |||
| 90-Day Total Return | -70.31% | |||
| Year to Date Total Return | -85.06% | |||
| 1-Year Total Return | -77.12% | |||
| 2-Year Total Return | -73.76% | |||
| 3-Year Total Return | -88.88% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -87.29% | |||
| 52-Week Low % Change | 17.94% | |||
| Price | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $46.80 | |||
| 52-Week Low Price | $5.05 | |||
| 52-Week Low Price (Date) | Apr 04, 2025 | |||
| 52-Week High Price (Date) | Jan 06, 2025 | |||
| Valuation | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 36.38M | |||
| Enterprise Value | -12.18M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -20.98 | |||
| Earnings Per Share Growth | -47.70% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 9.48 | |||
| Price/Book (Q) | -0.79 | |||
| Enterprise Value/Revenue (TTM) | -3.09 | |||
| Price | $5.95 | |||
| Enterprise Value/EBITDA (TTM) | 0.14 | |||
| Enterprise Value/EBIT | 0.14 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.28M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800-466-6059 | |||
| Address | One Corporate Drive South San Francisco, CA 94080 | |||
| Website | www.aligos.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,259.92% | |||
| Profit Margin | -3,326.00% | |||
| Management Effectiveness | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -50.29% | |||
| Return on Equity | -- | |||
| Income Statement | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.95M | |||
| Total Revenue (TTM) | 3.95M | |||
| Revenue Per Share | $0.63 | |||
| Gross Profit (TTM) | -66.33M | |||
| EBITDA (TTM) | -88.13M | |||
| EBIT (TTM) | -89.15M | |||
| Net Income (TTM) | -131.21M | |||
| Net Income Avl. to Common (TTM) | -131.21M | |||
| Total Revenue Growth (Q YOY) | -76.54% | |||
| Earnings Growth (Q YOY) | -194.53% | |||
| EPS Diluted (TTM) | -20.98 | |||
| EPS Diluted Growth (Q YOY) | -137.66% | |||
| Balance Sheet | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 56.94M | |||
| Cash Per Share (Q) | $9.06 | |||
| Total Current Assets (Q) | 62.14M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -28.97M | |||
| Current Ratio (Q) | 2.859 | |||
| Book Value Per Share (Q) | -$7.50 | |||
| Total Assets (Q) | 70.09M | |||
| Total Current Liabilities (Q) | 21.74M | |||
| Total Debt (Q) | 8.38M | |||
| Total Liabilities (Q) | 99.07M | |||
| Total Common Equity (Q) | -28.97M | |||
| Cash Flow | ALGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -18.28M | |||
| Cash from Financing (TTM) | 355.00K | |||
| Net Change in Cash (TTM) | -98.67M | |||
| Levered Free Cash Flow (TTM) | -46.99M | |||
| Cash from Operations (TTM) | -80.74M | |||
